Breaking News Instant updates and real-time market news.

CYTK

Cytokinetics

$8.65

-0.35 (-3.89%)

16:04
02/15/18
02/15
16:04
02/15/18
16:04

Cytokinetics reports Q4 EPS (75c), consensus (70c)

The company also announced financial guidance for 2018. The company anticipates cash revenue will be in the range of $17 to $23M, operating expenses will be in the range of $105 to $115M, and net cash utilization will be approximately $100M. Consensus estimates for FY18 revenue is $25.59M

  • 15

    Feb

  • 21

    Feb

CYTK Cytokinetics
$8.65

-0.35 (-3.89%)

11/22/17
11/22/17
DOWNGRADE
Target $10

Neutral
Cytokinetics downgraded after tirasemtiv discontinuation at Cantor Fitzgerald
As previously reported, Cantor Fitzgerald analyst Mara Goldstein downgraded Cytokinetics to Neutral from Overweight after the VITALITY-ALS trial failed and the company announced the discontinuation of the tirasemtiv program. While she sees opportunity for upside as clinical data emerge on omecamtiv and CK-2127107, she argues that the time to meaningful data and proximity to year-end makes a Neutral rating appropriate. Goldstein lowered her price target on Cytokinetics to $10 from $21.
11/22/17
NEED
11/22/17
DOWNGRADE
Target $12
NEED
Buy
Cytokinetics downgraded to Buy at Needham after failed tirasemtiv Phase 3
As reported earlier, Needham analyst Chad Messer downgraded Cytokinetics to Buy from Strong Buy and cut his price target to $12 from $22 after the company's Phase 3 study of tirasemtiv inamyotrophic lateral sclerosis failed to reach its efficacy endpoints. Messer says the culprit was the high dropout rates due to the tolerability issues of tirasemtiv. The analyst notes that the company will now turn its focus to developing CK-107, which has a superior tolerability profile. Messer adds that the Buy rating still reflects his expectations of potential value creation from CK-107 in FY18.
11/22/17
11/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Salesforce (CRM) downgraded to Neutral from Buy at Roth Capital with analyst Richard Baldry citing the 59% year-to-date rally in the shares. 2. Bloomin' Brands (BLMN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gregory Francfort citing news of Jana Partners' 8.7% stake and subsequent share price spike. 3. Halozyme (HALO) assumed with an Equal Weight from Overweight at Barclays with analyst Gena Wang saying she believes the potential of Halozyme's Enhanze technology is largely reflected in the stock following the recent rally. 4. Mallinckrodt (MNK) downgraded to Perform from Outperform at Oppenheimer with analyst Derek Archila saying he's been "flat out wrong" on the shares. 5. Cytokinetics (CYTK) was downgraded to Neutral from Overweight at Cantor Fitzgerald and to Buy from Strong Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/19/18
HCWC
01/19/18
NO CHANGE
Target $20
HCWC
Buy
Cytokinetics price target raised to $20 from $17 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Cytokinetics to $20 after spending time with management. CK-107 could be the molecule that resets the investment thesis in 2018, Pantginis tells investors in a research note. The analyst looks for a "quick turnaround" in 2018 and keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

HRTX

Heron Therapeutics

$24.70

0.28 (1.15%)

15:20
03/19/19
03/19
15:20
03/19/19
15:20
Options
6X average daily option volume in Heron Therapeautics driven by call spreads »

6X average daily option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

HNP

Huaneng Power

$23.42

-0.47 (-1.97%)

15:19
03/19/19
03/19
15:19
03/19/19
15:19
Downgrade
Huaneng Power rating change  »

Huaneng Power downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$43.88

0.21 (0.48%)

15:19
03/19/19
03/19
15:19
03/19/19
15:19
Options
Smartsheet options imply 12.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 05

    Apr

VALE

Vale

$13.90

0.62 (4.67%)

15:18
03/19/19
03/19
15:18
03/19/19
15:18
Hot Stocks
Vale reports reestablishment of Guaiba Island Terminal activities »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
03/19/19
03/19
15:17
03/19/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
03/19/19
03/19
15:16
03/19/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$23.24

0.54 (2.38%)

15:10
03/19/19
03/19
15:10
03/19/19
15:10
Conference/Events
Mallinckrodt management to meet with Mizuho »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

SYMC

Symantec

$23.27

0.19 (0.82%)

15:10
03/19/19
03/19
15:10
03/19/19
15:10
Options
Put buyers sizing up new positions in Symantec far downside strikes »

Put buyers sizing up new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

GATX

GATX

$76.90

0.21 (0.27%)

15:08
03/19/19
03/19
15:08
03/19/19
15:08
Conference/Events
GATX management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

BA

Boeing

$375.00

2.9 (0.78%)

15:08
03/19/19
03/19
15:08
03/19/19
15:08
Periodicals
DOT asks department watchdog to audit approval of Boeing 737, Bloomberg says »

Transportation Secretary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    May

BA

Boeing

$375.07

2.97 (0.80%)

15:05
03/19/19
03/19
15:05
03/19/19
15:05
Periodicals
Breaking Periodicals news story on Boeing »

DOT asks Inspector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    May

TME

Tencent Music

$19.33

0.2 (1.05%)

15:04
03/19/19
03/19
15:04
03/19/19
15:04
Options
Tencent options imply 12.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

NAII

Natural Alternatives International

$11.20

-0.17 (-1.50%)

15:01
03/19/19
03/19
15:01
03/19/19
15:01
Hot Stocks
Natural Alternatives says Court of Appeals rules in its favor in patent suit »

Natural Alternatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
03/19/19
03/19
15:00
03/19/19
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

KEM

Kemet

$18.34

0.02 (0.11%)

14:56
03/19/19
03/19
14:56
03/19/19
14:56
Conference/Events
Kemet management to meet with B. Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

DBD

Diebold

$11.07

-0.33 (-2.89%)

14:55
03/19/19
03/19
14:55
03/19/19
14:55
Options
Diebold put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$25.68

2.43 (10.45%)

, GOOG

Alphabet

$1,195.81

12.15 (1.03%)

14:54
03/19/19
03/19
14:54
03/19/19
14:54
Hot Stocks
AMD says Radeon GPUs being used for Google Stadia platform »

AMD (AMD) announced that…

AMD

AMD

$25.68

2.43 (10.45%)

GOOG

Alphabet

$1,195.81

12.15 (1.03%)

GOOGL

Alphabet Class A

$1,199.72

11.63 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

SIEN

Sientra

$9.26

0.05 (0.54%)

14:51
03/19/19
03/19
14:51
03/19/19
14:51
Hot Stocks
Breaking Hot Stocks news story on Sientra »

Sientra down 6% after FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNS

WNS Holdings

$52.87

-0.14 (-0.26%)

14:50
03/19/19
03/19
14:50
03/19/19
14:50
Conference/Events
WNS Holdings management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 26

    Mar

JCOM

j2 Global

$86.67

0.76 (0.88%)

14:49
03/19/19
03/19
14:49
03/19/19
14:49
Conference/Events
j2 Global management to meet with Wedbush »

Luncheon and Dinner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

FDX

FedEx

$182.02

-0.4 (-0.22%)

14:49
03/19/19
03/19
14:49
03/19/19
14:49
Options
Fedex options imply 8.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

SIEN

Sientra

$9.26

0.05 (0.54%)

14:48
03/19/19
03/19
14:48
03/19/19
14:48
Hot Stocks
FDA posts warning letter sent to Sientra »

In a letter dated March…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMASY

Inmarsat

$0.00

(0.00%)

14:46
03/19/19
03/19
14:46
03/19/19
14:46
Hot Stocks
Inmarsat confirms receipt of potential $7.21 per share offer from PE consortium »

The Board of Inmarsat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$269.61

0.15 (0.06%)

14:45
03/19/19
03/19
14:45
03/19/19
14:45
Periodicals
Tesla, Musk face dozens of suits, probes, CNBC says »

Tesla and CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

GLUU

Glu Mobile

$10.46

0.59 (5.98%)

14:45
03/19/19
03/19
14:45
03/19/19
14:45
Options
Glu Mobile call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.